Health Care Services

LifeStance Health

LifeStance Health Director Darren M. Black Sells ~5.9M Shares for $47.32M

LifeStance Health released FY2026 Q1 earnings on May 7 Pre-Market (EST), actual revenue USD 403.48 M (forecast USD 386.12 M), actual EPS USD 0.0367 (forecast USD 0.008)

LifeStance Health to Release FY2026 Q1 Earnings on May 7 Pre-Market EST, Forecast Revenue USD 386.15 M, EPS USD 0.008

LifeStance Health released FY2025 annual earnings on February 25 Pre-Market EST, actual revenue USD 1.424 B (forecast USD 1.42 B), actual EPS USD 0.02 (forecast USD -0.0036)

LifeStance Health released FY2025 Q4 earnings on February 25 Pre-Market EST, actual revenue USD 382.2 M (forecast USD 378.51 M), actual EPS USD 0.0294 (forecast USD -0.0003)

LifeStance Health to Release FY2025 Q4 Earnings on February 25, 2026 Pre-Market EST, Forecast Revenue USD 378.51 M, EPS USD -0.0003

Robert Besser Sold LifeStance Health Group Inc. Ordinary Shares

LifeStance Health released FY2025 Q3 earnings on November 6 Pre-Market EST, actual revenue USD 363.81 M (forecast USD 355.03 M), actual EPS USD 0.0027 (forecast USD -0.0084)

LifeStance Health released FY2025 9 Months Earnings on November 6 Pre-Market EST, with actual revenue of USD 1.042 B and EPS of USD -0.0054

LifeStance Health to Release FY2025 Q3 Earnings on November 6, Pre-Market EST; Forecast Revenue USD 355.03 M, EPS USD -0.0084

Caliendo Gives LifeStance Health Group a Strong Buy Rating

LifeStance Health released FY2025 Q2 earnings on August 7 Pre-Market EST, actual revenue USD 345.31 M (forecast USD 345.25 M), actual EPS USD -0.01 (forecast USD -0.026)

LifeStance Health released FY2025 Semi-Annual earnings on August 7 Pre-Market (EST), actual revenue USD 678.28 M, actual EPS USD -0.01

LifeStance Health to Release FY2025 Q2 Earnings on August 7, Pre-Market EST; Forecast Revenue USD 344.87 M, EPS USD -0.0273

LifeStance Health Group Inc. to Release Q2 2025 Earnings Report

LifeStance Health's Financial Status Raises Concerns

LifeStance Health's CMO Disposes of Company Common Stock

LifeStance Health Files Eric P. Palmer as Beneficial Owner Statement

LifeStance Health CMO Disposes of Common Stock

LifeStance Annual Shareholders Meeting Elects New Directors and Approves Auditor

OPTIMI HEALTH CORP

HCW Biologics

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

Micware

GCL Global

Silexion Therapeutics

EMMIS ACQUISITION CORP. ORD USD0.0001 (S/R 12/09/2030)

Capstone

HORIZON SPACE ACQUISITION II CORP COM USD0.0001 30/03/2026(SUB/RIGHTS)

Bristol-Myers Squibb Company

LFST

LifeStance Health Group (LFST) shares closed at $7.65, showing mixed short-term returns but a strong 1-year total shareholder return of 30.99%. Analysts suggest a fair value of $9.00, indicating the stock is undervalued by about 15%. The company's growth is driven by investments in AI and digital technology, although risks such as reimbursement pressure and clinician retention could impact profitability. The current P/E ratio of 127.9x is significantly higher than industry averages, raising questions about future growth expectations.

Simplywall

A Look At LifeStance Health Group (LFST) Valuation After Recent Share Price Momentum And Earnings Expectations

LifeStance Health Group, Inc. (LFST) has priced a secondary public offering of 35 million shares at $8.15 each, expected to generate $285 million for selling stockholders. LifeStance will repurchase 6 million shares at the same price. The offering is set to close around May 12, 2026. Additionally, Q1 2026 revenue rose 21% to $403.5 million, with net income increasing to $14.2 million. The company raised its full-year revenue guidance to $1.640-$1.680 billion, with an expected Adjusted EBITDA of $200-$220 million.

nasdaq

SPDR S&P Health

Health Care Select Sector SPDR

VG Health

iShares Global Healthcare

iShares US Healthcare Providers

JPMorgan Chase

Nasdaq

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

LifeStance Prices $285M Secondary Offering; Q1 Revenue Up 21%

Earnings Watch

LifeStance Health | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 403.48 M

LifeStance Health Group, Inc. announced a secondary public offering of 35 million shares of its common stock by certain stockholders, with proceeds going to them. The company will not sell any shares or receive proceeds. Additionally, LifeStance has authorized the repurchase of 6 million shares from the underwriter, J.P. Morgan, subject to the offering's completion. The offering is detailed in a prospectus filed with the SEC. LifeStance is a major provider of mental health care in the U.S., employing over 8,300 professionals across 33 states.

StockTitan

Broadridge Financial Solution

LifeStance Health Group Announces Launch of Secondary Public Offering | LFST Stock News

LifeStance Health Group's stock surged over 20% following a strong earnings report, showcasing a 21% revenue increase to $403.5 million in Q1 and a net income rise to $14.2 million. Analysts were surprised by the results, which exceeded expectations. The company raised its full-year revenue guidance to $1.64-$1.68 billion, reflecting growing demand for mental healthcare services. Despite this positive performance, it was noted that LifeStance was not among the top 10 stocks recommended by The Motley Fool's Stock Advisor.

LifeStance Health(LFST.US)

A Look At LifeStance Health Group (LFST) Valuation After Recent Share Price Momentum And Earnings Expectations

LifeStance Prices $285M Secondary Offering; Q1 Revenue Up 21%

LifeStance Health | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 403.48 M

LifeStance Health Group Announces Launch of Secondary Public Offering | LFST Stock News

Why LifeStance Health Group Zoomed 20% Higher Today